Price movement over the last 24 hours
AdaptHealth Corp vs Chubb Ltd — how do they compare? AdaptHealth Corp trades at $10.06 (market cap $1.38B), while Chubb Ltd trades at $357.08 (market cap $139.36B). The key difference: Chubb Ltd is far larger — about 101× AdaptHealth Corp's market cap, and Chubb Ltd pays a 1.14% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | CB | |
|---|---|---|
Market Cap | $1.38B | $139.36B |
Sector | Health | Financials |
52-Week High | $13.38 | $361.17 |
52-Week Low | $8.68 | $265.99 |
Enterprise Value | $3.33B | $160.41B |
Dividend Yield | — | 1.14% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Chubb (CB) trades at $359.30, down 0.52% on the day but near its 52-week high, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $59.78B in 2025 to projected $61.2B in 2026, and a net income margin of 18.46%. Recent news highlights premium growth and disciplined underwriting as key strengths.
Outlook remains positive with analyst consensus favoring Buy ratings (52.38%) and a price target of $341.90, though risks include catastrophe losses and softer commercial pricing. The stock's valuation at P/E 12.61 offers value, but investors should monitor Q2 2026 earnings due July 22, 2026, for confirmation of growth trends.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →